Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V81262 | QEQLERALNSS TFA | QEQLERALNSS TFA is an erythropoietin-derived helix B surface peptide (HBSP) with tissue protective activity. | |
|
V39273 | QN523 | 878581-60-3 | QN523 is a novel scaffold with reactive molecule-like properties that showed potent in vitro cytotoxic effect in 12 cancer cell lines. |
|
V52628 | Quercetin-d3 (quercetin d3) | 263711-79-1 | Quercetin-d3 is the deuterated form of Quercetin. |
|
V54875 | Quercetin-d5 (quercetin d5) | 263711-78-0 | Quercetin-d5 is a deuterated form of Quercetin. |
|
V54892 | Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) | 1228538-47-3 | Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody (mAb). |
|
V51920 | Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) | 875320-31-3 | Quisinostat di-HCl (JNJ-26481585 di-HCl) is an orally bioactive and highly effective pan-HDAC inhibitor (antagonist) with IC50s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM and HDAC11 for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11 respectively. |
|
V54945 | RA-V | 64725-24-2 | RA-V is a cyclic hexapeptide. |
|
V53372 | RA375 | 2649154-57-2 | RA375 is an inhibitor (blocker/antagonist) of RPN13 (26S proteasome subunit). |
|
V52610 | Rabeprazole-d3 sodium (LY307640-d3 sodium) | 1216494-11-9 | Rabeprazole-d3 (sodium)m is the deuterated form of Rabeprazole sodium. |
|
V54816 | Rabeprazole-d4 (LY307640-d4) | 934295-48-4 | Rabeprazole-d4 is a deuterated form of Rabeprazole. |
|
V54993 | Ragifilimab (INCAGN-1876) | 2207590-51-8 | Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody (mAb) targeting glucocorticoid-induced TNFR-related protein (GITR). |
|
V52677 | Ramipril-d3 (ramipril-d3) | 2673269-81-1 | Ramipril-d3 is the deuterium labelled form of Ramipril. |
|
V56417 | Ramipril-d5 (ramipril d5) | 1132661-86-9 | Ramipril-d5 is the deuterium labelled form of Ramipril. |
|
V55007 | Ranevetmab (NV-01) | 1632282-27-9 | Ranevetmab (NV-01) is a canine-derived anti-NGF monoclonal antibody (mAb). |
|
V39199 | RapaBlock (ZZY05-092) | 2474076-02-1 | RapaBlock is a potent, non-immunosuppressive and BBB (blood-brain barrier) non-permeable/penetrable FKBP12 ligand. |
|
V39197 | Rapanone | 573-40-0 | Rapanone is a natural benzoquinone. |
|
V52022 | Raptinal | 1176-09-6 | Raptinal directly activates caspase-3 and can initiate the caspase-dependent intrinsic pathway of apoptosis. |
|
V39196 | Ravagalimab (ABBV-323) | 2050816-56-1 | Ravagalimab (ABBV-323) is a CD40 antagonist (EC50= 3.7 nM). |
|
V86031 | RB-07-16 | ||
|
V54373 | rel-Zotatifin (rel-eFT226) | 2098191-54-7 | reli-Zotatifin is the racemic isomer of Zotatifin. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
